Clene INC 10-Q quarterly reports

Clene Inc. reported significant net losses and cash outflows in its Q2 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern.

Clene Inc. reports Q1 2026 results, highlighting progress in ALS and MS drug development, while facing ongoing financial challenges and a going concern assessment.

Clene Inc. reported a reduced net loss in Q3 2025 and advanced its CNM-Au8 clinical programs for ALS and MS, but faces substantial doubt about its ability to continue as a going concern.

Clene Inc. reported a reduced net loss in Q2 2025, while continuing to advance its lead drug candidate CNM-Au8 for ALS and MS, despite ongoing liquidity concerns and internal control weaknesses.

Clene Inc. reports a net loss of $751,000 for Q1 2025, provides updates on its clinical programs, and acknowledges substantial doubt about its ability to continue as a going concern.

Clene Inc. reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and a recent capital raise, while also acknowledging substantial doubt about its ability to continue as a going concern.

Clene Inc. released its second quarter 2024 financial results, highlighting ongoing clinical trial progress and a recent reverse stock split.

Clene Inc. reported its financial results for the first quarter of 2024, highlighting ongoing clinical program developments and financial challenges.